Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

Literature DB >> 25083126

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

Sapna Parmar, Khilna Patel, Javier Pinilla-Ibarz.

Abstract

Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

Entities: Chemical Disease

Year: 2014 PMID： 25083126 PMCID： PMC4103574

Source DB: PubMed Journal: P T ISSN： 1052-1372

15 in total

Review 1. How I treat CLL up front.

Authors: John G Gribben
Journal: Blood Date: 2009-10-22 Impact factor: 22.113

Review 2. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.

Authors: Amin Aalipour; Ranjana H Advani
Journal: Br J Haematol Date: 2013-09-24 Impact factor: 6.998

Review 3. Chronic lymphocytic leukemia.

Authors: John C Byrd; Stephan Stilgenbauer; Ian W Flinn
Journal: Hematology Am Soc Hematol Educ Program Date: 2004

Review 4. Familial chronic lymphocytic leukemia: what does it mean to me?

Authors: Susan L Slager; Neil E Kay
Journal: Clin Lymphoma Myeloma Date: 2009

5. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors: Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal: J Clin Oncol Date: 2012-10-08 Impact factor: 44.544

6. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal: Blood Date: 2008-01-23 Impact factor: 22.113

Review 7. The immunodeficiency of chronic lymphocytic leukaemia.

Authors: A D Hamblin; T J Hamblin
Journal: Br Med Bull Date: 2008-08-27 Impact factor: 4.291

8. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

Review 9. Ibrutinib and novel BTK inhibitors in clinical development.

Authors: Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal: J Hematol Oncol Date: 2013-08-19 Impact factor: 17.388

10. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.

Authors: Julio C Chavez; Eva Sahakian; Javier Pinilla-Ibarz
Journal: Core Evid Date: 2013-05-16

19 in total

Review 1. Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

Authors: R Andrew Harkins; Sharvil P Patel; Christopher R Flowers
Journal: Cancer J Date: 2019 Nov/Dec Impact factor: 3.360

2. Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia.

Authors: Eric Wiedower; Felicia Hare; Adam Arthur; Jason Chandler; Michael G Martin
Journal: Ther Adv Hematol Date: 2016-05-17

Review 3. Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors: Zhengrui Xiao; Irina Murakhovskaya
Journal: Pharmaceutics Date: 2022-05-11 Impact factor: 6.525

Review 4. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Authors: Eric D Eisenmann; Zahra Talebi; Alex Sparreboom; Sharyn D Baker
Journal: Basic Clin Pharmacol Toxicol Date: 2021-06-28 Impact factor: 4.080

5. Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.

Authors: Nishika Karbhari; Hugo Lara-Martinez; John M Hill
Journal: Case Rep Oncol Date: 2022-03-30

Review 6. Dual effect of oxidative stress on leukemia cancer induction and treatment.

Authors: Udensi K Udensi; Paul B Tchounwou
Journal: J Exp Clin Cancer Res Date: 2014-12-18

7. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.

Authors: Jan de Jong; Donna Skee; Joe Murphy; Juthamas Sukbuntherng; Peter Hellemans; Johan Smit; Ronald de Vries; Juhui James Jiao; Jan Snoeys; Erik Mannaert
Journal: Pharmacol Res Perspect Date: 2015-06-24

Review 8. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors: Smita Y Patel; Javier Carbone; Stephen Jolles
Journal: Front Immunol Date: 2019-02-08 Impact factor: 7.561

Review 9. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors: Abdulaziz B Hamid; Ruben C Petreaca
Journal: Cancers (Basel) Date: 2020-04-09 Impact factor: 6.639

10. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Authors: Tobias Litzenburger; Jürgen Steffgen; Ewald Benediktus; Fabian Müller; Armin Schultz; Elliott Klein; Meera Ramanujam; Christian Harcken; Alpana Gupta; Jing Wu; Sabrina Wiebe; Xiujiang Li; Mary Flack; Steven J Padula; Sudha Visvanathan; Andreas Hünnemeyer; Jianan Hui
Journal: Br J Clin Pharmacol Date: 2020-11-20 Impact factor: 3.716